IP Library Granted Patent US 10,534,002
Granted Patent B2
US 10,534,002 · App. 15/476,118 · Granted Jan 14, 2020

Selected reaction monitoring assays

Inventors: Paul Edward Kearney (Seattle, WA); Xiao-Jun Li (Bellevue, WA); Clive Hayward (Seattle, WA); Miguel Dominguez Geeraerts (Pierrefonds, CA)
Assignee: Biodesix, Inc.
G01N33/57484C07K7/06C07K7/08G01N27/62G01N33/6848G01N2333/705G01N2458/15G01N2560/00G01N2570/00G01N2800/2821
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,534,002
App. No.
15/476,118
Granted
Jan 14, 2020
Kind
B2
Abstract

Provided herein are methods for developing selected reaction monitoring mass spectrometry (LC-SRM-MS) assays.

Claims (12)

1. A composition comprising isolated synthetic peptides said composition comprising ALQASALK (SEQ ID NO: 58), GFLLLASLR (SEQ ID NO: 1644), LGGPEAGLGEYLFER (SEQ ID NO: 596), VEIFYR (SEQ ID NO: 941), INPASLDK (SEQ ID NO: 153) and TSYQVYSK (SEQ ID NO: 155).

2. A composition comprising at least 10 isolated synthetic peptides said composition comprising at least 2 isolated synthetic peptides of each TSP1, ALDOA, FRIL, LG3BP, and C163A, and wherein the at least two isolated synthetic peptides are selected from ADDGRPFPQVIK (SEQ ID NO: 57), ALQASALK (SEQ ID NO: 58), QLLLTADDR (SEQ ID NO: 60), ALFQDIK (SEQ ID NO: 593), DDV ALEGVSHFFR (SEQ ID NO: 594), KPAEDEWGK (SEQ ID NO: 595), LGGPEAGLGEYLFER(SEQ IDNO: 596), LNQALLDLHALGSAR (SEQ ID NO: 597), MGDHLTNLHR (SEQ ID NO: 598), ASHEEVEGL VEK (SEQ ID NO: 938), STHTLDLSR (SEQ ID NO: 940), VEIFYR (SEQ ID NO: 941), YSSDYFQAPSDYR (SEQ ID NO: 942), FQDLVDA VR (SEQ ID NO: 1641), FTGSQPFGQGVEHATANK (SEQ ID NO: 1642), FVFGTIPEDILR (SEQ ID NO: 1643), GFLLLASLR (SEQ ID NO: 1644), INPASLDK (SEQ ID NO: 153), LEVFYNGAWGTVGK (SEQ ID NO: 154), TSYQVYSK (SEQ ID NO: 155), and GTSQNDPNWVVR (SEQ ID NO: 1645).

3. The composition of claim 2 , wherein at least one of the isolated synthetic peptides is isotopically labeled.

4. The composition of claim 2 , wherein the measured quantity of each of the at least 2 isolated synthetic peptides of each TSP1, ALDOA, FRIL, LG3BP, and C163A is known.

5. The composition of claim 2 , further comprising one or more polar solvents.

6. The composition of claim 2 , further comprising an additional five isolated synthetic peptides of at least one protein selected from LRP1, BGH3, COIA1, TETN, TSP1, ALDOA, GRP78, ISLR, FRIL, LG3BP, PRDX1, FIBA, KIT, GGH, C163A and GSLGI.

7. The composition of claim 2 , further comprising an additional five isolated synthetic peptides of at least one protein selected from APOE, BASP1, CD14, FOXA2 or HSPB 1.

8. A composition comprising at least 25 isolated synthetic peptides said composition comprising at least five isolated synthetic peptides of each TSP1, ALDOA, FRIL, LG3BP, and C163A wherein the at least five isolated synthetic peptides are selected from ADDGRPFPQVIK (SEQ ID NO: 57), ALQASALK (SEQ ID NO: 58), QLLLTADDR (SEQ ID NO: 60), ALFQDIK (SEQ ID NO: 593), DDV ALEGVSHFFR (SEQ ID NO: 594), KPAEDEWGK (SEQ IDNO: 595), LGGPEAGLGEYLFER(SEQ IDNO: 596), LNQALLDLHALGSAR (SEQ ID NO: 597), MGDHLTNLHR (SEQ ID NO: 598), ASHEEVEGLVEK (SEQ ID NO: 938), STHTLDLSR (SEQ ID NO: 940), VEIFYR (SEQ ID NO: 941), YSSDYFQAPSDYR (SEQ ID NO: 942), FQDLVDAVR (SEQ ID NO: 1641), FTGSQPFGQGVEHATANK (SEQ ID NO: 1642), FVFGTIPEDILR (SEQ ID NO: 1643), GFLLLASLR (SEQ ID NO: 1644), INPASLDK (SEQ ID NO: 153), LEVFYNGAWGTVGK (SEQ ID NO: 154), TSYQVYSK (SEQ ID NO: 155), and GTSQNDPNWVVR (SEQ ID NO: 1645).

9. The composition of claim 8 , wherein the at least five isolated synthetic peptides are selected from GFLLLASLR (SEQ ID NO: 1644), LGGPEAGLGEYLFER (SEQ ID NO: 596), ALQASALK (SEQ ID NO: 58), VEIFYR (SEQ ID NO: 941), INPASLDK (SEQ ID NO: 153), LEVFYNGAWGTVGK (SEQ ID NO: 154), and TSYQVYSK (SEQ ID NO: 155).

10. A method comprising analyzing the composition of claim 8 using mass spectrometry.

11. The method of claim 10 , wherein the method uses selected reaction monitoring mass spectrometry.

12. A method comprising analyzing the composition of claim 8 using Enzyme-Linked Immunosorbent Assay (ELISA).

Assignments (3)
SECURITY AGREEMENT Recorded Nov 22, 2022
From: BIODESIX, INC.
To: PERCEPTIVE CREDIT HOLDINGS IV, LP
Reel/Frame 061977/0919 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 20, 2018
From: INTEGRATED DIAGNOSTICS, INC.
To: BIODESIX, INC.
Reel/Frame 046416/0688 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2017
From: KEARNEY, PAUL EDWARD; LI, XIAO-JUN; HAYWARD, CLIVE; GEERAERTS, MIGUEL DOMINGUEZ
To: INTEGRATED DIAGNOSTICS, INC.
Reel/Frame 042252/0823 →
Continuity (5)
Continuation 14738146 · Jun 12, 2015
Continuation 13725098 · Dec 21, 2012
Provisional Application 61578718 · Dec 21, 2011
Provisional Application 61614818 · Mar 23, 2012
Related Publication 20170212120A1 · Jul 27, 2017